Nephros, Inc. (OTCQB:NEPH),(the “Company”) a commercial stage medical
device company that develops and sells high performance liquid
purification ultrafilters and an on-line mid-dilution hemodiafiltration
system for use with hemodialysis machines for the treatment of End Stage
Renal Disease patients, announced today that data about Nephros’ DSU-D
ultrafilter was published online in Case Reports in Nephrology and
Dialysis.
Title: Benefits of the Nephros Dual Stage Ultrafilter in Chronic
Hemodialysis Patients: Evidence for Improved ESA Responsiveness
The full study can be found via the following weblink: https://www.karger.com/Article/FullText/443328
Nephros Challenge Ending Soon
In September 2015, the Company announced the Nephros Challenge, a
program offering a money-back guarantee to encourage dialysis clinics to
evaluate the performance improvement potential from using Nephros
ultrafilters. The ultrafilters are used on the water and bicarbonate
concentrate lines which feed into a hemodialysis machine. The
ultrafilters retain particles as small as five nanometers (5nm),
preventing bacteria, viruses and endotoxins from entering the machine.
Nephros’ proprietary filter fiber provides superior protection and
enables a five log reduction in levels of endotoxin, which is a key
contributor to vascular inflammation in dialysis patients. Nephros
ultrafilters are FDA 510(k) cleared for a 12-month product life when
used in dialysis clinics.
The Nephros Challenge program continues until March 31, 2016. For
dialysis clinics that wish to enroll in the Nephros Challenge before the
promotion ends, they can contact their water system provider or contact
Nephros at TheChallenge@Nephros.com.
About Nephros, Inc.
Nephros is a commercial stage medical device company that develops and
sells high performance liquid purification filters, as well as a
hemodiafiltration system for the treatment of patients with End Stage
Renal Disease. Its filters, which it calls ultrafilters, are used
primarily in medical applications. Nephros ultrafilters are used by
dialysis centers for the removal of biological contaminants from the
water and bicarbonate concentrate feeding hemodialysis devices.
Additionally, Nephros ultrafilters are used in hospitals and medical
clinics as an aid in infection control by retaining bacteria (i.e.
Legionella, Pseudomonas), virus and endotoxin from water used by
patients.
For more information about Nephros, please visit the company’s website
at www.nephros.com.
Forward-Looking Statements
This release contains forward-looking statements that are subject to
various risks and uncertainties. Such statements include statements
regarding the Nephros Challenge and other statements that are not
historical facts, including statements which may be accompanied by the
words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,”
“potential” or similar words. Actual results could differ materially
from those described in these forward-looking statements due to certain
factors, including changes in business, economic and competitive
conditions, regulatory reforms, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties are
detailed in Nephros Inc.’s reports filed with the U.S. Securities and
Exchange Commission, including with respect to Nephros, its Annual
Report on Form 10-K for the year ended December 31, 2014. Nephros, Inc.
does not undertake any responsibility to update the forward-looking
statements in this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160118005410/en/
Copyright Business Wire 2016